HomeNewsNeuroscienceMultiple Sclerosis

  • Successful results for Multiple Sclerosis MAb GNbAC1 announced by GeNeuro and Servier in Phase 2b CHANGE-MS Study

    • March 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Secondary Progressive MS – Pharmascroll Report predicts increase in market activity in next 5-10 years

    • March 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments

    Expected launch of Siponimod and a strong pipeline in SPMS indicates a strong SPMS focus. SPMS- Detailed overview provides an overview of SPMS in detail, highlights the SPMS epidemiology, elaborates on the drugs prescribed and expected to be prescribed along with the sales and patient numbers forecast.

    read more

  • Siponimod significantly improves patient outcomes in SPMS, as per latest study

    • March 23, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Clinical outcomes assessed for older patients discontinuing MS DMTs

    • March 23, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • EHP-101 shows potential for Remyelination & Disease Modification in MS

    • March 22, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • MS patients might suffer from poor perceptions of smell, claims a latest study

    • March 21, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Stem cell transplant offers promise as MS treatment as per latest trial results

    • March 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA assisting in withdrawal of Zinbryta (daclizumab) from the market

    • March 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more